Avidity Biosciences Inc. (RNA)
NASDAQ: RNA
· Real-Time Price · USD
44.47
-2.00 (-4.30%)
At close: Aug 18, 2025, 3:59 PM
44.03
-0.99%
Pre-market: Aug 19, 2025, 04:01 AM EDT
-4.30% (1D)
| Bid | 41.68 |
| Market Cap | 5.72B |
| Revenue (ttm) | 8.93M |
| Net Income (ttm) | -369.22M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -12.49 |
| Forward PE | -10.53 |
| Analyst | Buy |
| Ask | 47.99 |
| Volume | 1,514,653 |
| Avg. Volume (20D) | 2,382,448 |
| Open | 46.11 |
| Previous Close | 46.47 |
| Day's Range | 44.37 - 46.49 |
| 52-Week Range | 21.51 - 56.00 |
| Beta | 0.95 |
Analyst Forecast
According to 0 analyst ratings, the average rating for RNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Avidity Biosciences Inc. is scheduled to release its earnings on
Nov 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+26.14%
Avidity Biosciences shares are trading higher foll...
Unlock content with
Pro Subscription
3 months ago
-18.65%
Shares of vaccine and gene therapy stocks are trading lower after FDA Commissioner Marty Makary reportedly named Vinay Prasad as director of the Center for Biologics and Research.
